Cargando…
113: SPECIFIC TARGETING OF HER2-POSITIVE BREAST CANCER CELL LINE (SK-BR3) USING IDARUBICIN-LOADED ANTI-HER2 IMMUNOLIPOSOME
Cytotoxic chemotherapy drugs which are used for treating malignant cells cannot distinguish between normal and cancerous cells. This would lead to adverse side effects. Moreover, drug resistance is another major problem of the classical chemotherapy during the treatment period. Recently, various the...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BMJ Publishing Group
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5759544/ http://dx.doi.org/10.1136/bmjopen-2016-015415.113 |